×
159
Fashion Jobs
PUMA
Junior Manager go-to-Market Operations Nordic
Permanent · Solna
PUMA
Senior Key Account Manager Running Nordic
Permanent · Solna
PUMA
Senior Marketing Manager Cobra Puma Golf Europe
Permanent · Solna
PUMA
Strategic Key Account Manager Pure Players
Permanent · Solna
LEVI'S
Key Account Manager
Permanent · Stockholm
H&M
Global Head of Marketing h&m Sport
Permanent · Stockholm
H&M
Project Leader For Material Certification And Material Trademark Within Group Compliance
Permanent · Stockholm
PUMA
Project Manager IT Sap
Permanent · Solna
H&M
Art Director – h&m Group Communications
Permanent · Stockholm
H&M
Data Analyst to Predictive Analytics Team @h&m Business Tech
Permanent · Stockholm
H&M
Data Analyst to an Inventory Optimization Team in Business Tech
Permanent · Stockholm
H&M
Business Minded Data Specialist to h&m Group
Permanent · Stockholm
H&M
Scrum Master (Service Now) to Support And Operations Toolings Team at h&m Business Tech
Permanent · Stockholm
H&M
we Are Looking For Business Intelligence Analysts to Group Expansion, h&m
Permanent · Stockholm
H&M
Business Intelligence Analyst
Permanent · Stockholm
H&M
Cyber Security Trainer
Permanent · Stockholm
H&M
Security Advisor
Permanent · Stockholm
H&M
h&m is Looking For a Business Expert For Allocation Precision
Permanent · Stockholm
H&M
Power bi Specialist to Kpi Dashboards Within Business Tech
Permanent · Stockholm
H&M
ai Learning & Development Manager
Permanent · Stockholm
H&M
Import-Export Manager to h&m Distribution Centre in Eskilstuna
Permanent · Eskilstuna
H&M
Scrum Master to Support & Operation Tooling, Monitoring & Insights Team at h&m Business Tech
Permanent · Stockholm
By
Reuters API
Published
Apr 19, 2022
Reading time
2 minutes
Share
Download
Download the article
Print
Click here to print
Text size
aA+ aA-

J&J suspends sales forecast for COVID vaccine, cuts profit view

By
Reuters API
Published
Apr 19, 2022

Johnson & Johnson on Tuesday cut its full-year profit expectation and said it could no longer provide a forecast for sales of its COVID-19 vaccine because of demand uncertainty as well as surplus supply of other shots.


Johnson & Johnson



The company had earlier predicted as much as $3.5 billion in sales from the single-dose vaccine, which has fared poorly compared to rivals due to low demand in the United States and safety concerns.

The vaccine, which is sold at a "not-for-profit" price, brought in $457 million in the first quarter. Its sales last year had underperformed rival mRNA shots also due to manufacturing bottlenecks and weak global demand.

Pfizer Inc has forecast $32 billion in 2022 sales from its COVID vaccine developed with BioNTech, while Moderna has forecast $21 billion.

J&J now expects full-year adjusted profit forecast to be between $10.15 and $10.35 per share due to a stronger dollar, lower than the prior expectation of $10.40 to $10.60 per share.

Overall first-quarter sales of $23.43 billion missed Refinitiv estimates of $23.61 billion.

"The slight miss was really around the COVID-19 vaccine and quite frankly it met our internal expectations. There was just a disconnect into how the Street assumed it was going to play out over the year," Chief Financial Officer Joseph Wolk told CNBC.

While sales in its consumer health and medical device units beat expectations, sales of $12.87 billion from its large pharmaceuticals unit fell below estimates of $13.6 billion.

J&J warned that supply chain constraints in its consumer health unit would hit sales of its skin health and beauty products for the rest of the year.

Excluding items, J&J earned $2.67 per share, beating market expectation of $2.56 per share.

Citi analyst Joanne Wuensch said the company's earnings "raise more questions than it answers" and investors would be looking for more clarity on the impact of the Russia-Ukraine crisis and soaring inflation.
 

© Thomson Reuters 2022 All rights reserved.

Tags :
Business